ClearNote Health Inc.

ClearNote Health developed Avantect®, a liquid biopsy test that detects pancreatic and other high-mortality cancers early through a standard blood draw in Stage I/II. Powered by our proprietary epigenomic platform and AI, Avantect® enables early intervention for high-risk patients, offering a new paradigm in cancer detection and improving patient outcomes.